These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 27754959)

  • 41. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times.
    Papapetrou PD; Polymeris A
    Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers.
    Giovanella L; Crippa S; Cariani L
    Int J Biol Markers; 2008; 23(2):129-31. PubMed ID: 18629788
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
    Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
    Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PDN-21: possible tumor marker for medullary thyroid carcinoma.
    Takami H; Shikata J; Horie H; Sekine K; Ito K
    J Surg Oncol; 1990 Aug; 44(4):205-7. PubMed ID: 2385096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.
    Thomas CM; Asa SL; Ezzat S; Sawka AM; Goldstein D
    Curr Oncol; 2019 Oct; 26(5):338-344. PubMed ID: 31708652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can procalcitonin be useful for medullary thyroid cancer?
    Kaczka K; Mikosiński S; Fendler W; Jałocha-Kaczka A; Pomorski L
    Endokrynol Pol; 2010; 61(5):430-6. PubMed ID: 21049453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.
    Iacobone M; Niccoli-Sire P; Sebag F; De Micco C; Henry JF
    World J Surg; 2002 Aug; 26(8):886-90. PubMed ID: 12016469
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
    Łacka K; Michałek K; Majewski P
    Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases.
    Hahm JR; Lee MS; Min YK; Lee MK; Kim KW; Nam SJ; Yang JH; Chung JH
    Thyroid; 2001 Jan; 11(1):73-80. PubMed ID: 11272100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection.
    Kaczka K; Mikosiński S; Fendler W; Celnik A; Pomorski L
    Adv Clin Exp Med; 2012; 21(2):169-78. PubMed ID: 23214280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma.
    Algeciras-Schimnich A; Preissner CM; Theobald JP; Finseth MS; Grebe SK
    J Clin Endocrinol Metab; 2009 Mar; 94(3):861-8. PubMed ID: 19088163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
    Smith A; Galli M; Piga I; Denti V; Stella M; Chinello C; Fusco N; Leni D; Manzoni M; Roversi G; Garancini M; Pincelli AI; Cimino V; Capitoli G; Magni F; Pagni F
    J Proteomics; 2019 Jan; 191():114-123. PubMed ID: 29581064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
    Mucha SA; Kunert-Radek J; Pomorski L
    Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.
    Verbeek HH; de Groot JWB; Sluiter WJ; Muller Kobold AC; van den Heuvel ER; Plukker JT; Links TP
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD010159. PubMed ID: 32176812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.
    Zarkesh M; Arab N; Tavangar SM; Nozhat Z; Fanaei SM; Hedayati M
    Pathol Res Pract; 2022 Jan; 229():153694. PubMed ID: 34929598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Usefulness of Serum Calcitonin in Patients Without a Suspicious History of Medullary Thyroid Carcinoma and with Thyroid Nodules Without an Indication for Fine-Needle Aspiration or with Benign Cytology.
    Rosario PW; Calsolari MR
    Horm Metab Res; 2016 Jun; 48(6):372-276. PubMed ID: 27203410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Kurzrock R; Atkins J; Wheler J; Fu S; Naing A; Busaidy N; Hong D; Sherman S
    Ann Oncol; 2013 Sep; 24(9):2256-61. PubMed ID: 23676418
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progastrin-Releasing Peptide As a Diagnostic Biomarker of Pulmonary and Non-Pulmonary Neuroendocrine Neoplasms.
    La Salvia A; Fanciulli G
    Endocr Res; 2024; 49(4):243-250. PubMed ID: 39041209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules.
    Costante G; Meringolo D; Durante C; Bianchi D; Nocera M; Tumino S; Crocetti U; Attard M; Maranghi M; Torlontano M; Filetti S
    J Clin Endocrinol Metab; 2007 Feb; 92(2):450-5. PubMed ID: 17119000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevation of serum pro-gastrin-releasing peptide in patients with medullary thyroid carcinoma and small cell lung carcinoma.
    Ide A; Ashizawa K; Ishikawa N; Ishii R; Ando T; Abe Y; Sera N; Usa T; Tominaga T; Ejima E; Nakashima M; Ito K; Ito K; Eguchi K
    Thyroid; 2001 Nov; 11(11):1055-61. PubMed ID: 11762716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.